Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
16-30 of 4049 results
Amgen, UCB explore option of second course of treatment with evenity
Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.
Contract Research & Services > Clinical Trials > News
Corbus’ anabasum meets safety and tolerability goals in cystic fibrosis study
By PBR Staff Writer
A phase 2 trial evaluating Corbus Pharmaceuticals’ multiple doses of anabasum (Resunab) has met its primary objective in patients with cystic fibrosis, demonstrating an acceptable safety and tolerability profile with no severe adverse events.
Contract Research & Services > Clinical Trials > News
Ritter reports topline phase 2b/3 results for lactose intolerance treatment RP-G28
Ritter Pharmaceuticals' lactose intolerance treatment, RP-G28, demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial.
Contract Research & Services > Clinical Trials > News
Summit to extend PhaseOut DMD trial for ezutromid
Summit Therapeutics has announced that, subject to regulatory approval, it will go ahead with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial studying the utrophin modulator ezutromid.
Contract Research & Services > Clinical Trials > News
Allergan, Paratek’s acne drug succeeds in two phase 3 trials
By PBR Staff Writer
Allergan and Paratek Pharmaceuticals’ acne drug sarecycline has met its primary efficacy endpoints in two phase 3 trials.
Contract Research & Services > Clinical Trials > News
Xenon’s acne drug XEN801 fails in phase 2 trial
By PBR Staff Writer
A phase 2 trial of Xenon Pharmaceuticals’ acne drug XEN801 has failed to meet its efficacy endpoints in patients having moderate to severe acne.
Contract Research & Services > Clinical Trials > News
Akashi gets FDA nod to restart clinical development of DMD drug HT-100
Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).
Contract Research & Services > Clinical Trials > News
Novartis’ serelaxin fails to meet primary endpoint in heart failure study
By PBR Staff Writer
Novartis' RLX030 (serelaxin) has failed to meet its primary endpoint in a phase III acute heart failure (AHF) study.
Contract Research & Services > Clinical Trials > News
Lilly’s abemaciclib meets primary endpoint in phase 3 breast cancer trial
By PBR Staff Writer
A phase 3 study of Lilly’s breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS).
Contract Research & Services > Clinical Trials > News
Nektar’s NKTR-181 shown to reduce chronic pain in phase 3 trial
Nektar Therapeutics’ NKTR-181 has met primary and secondary endpoints in phase 3 SUMMIT-07 study in chronic pain.
Contract Research & Services > Clinical Trials > News
Novartis’ heart failure drug Entresto improves glycemic control in Phase III study
Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril.
Contract Research & Services > Clinical Trials > News
Amgen's Repatha lowers heart attack, stroke risk in phase 3 study
By PBR Staff Writer
A phase 3 study has demonstrated that Amgen’s cholesterol drug Repatha reduces low-density lipoprotein cholesterol (LDL-C) levels and risk of cardiovascular events.
Contract Research & Services > Clinical Trials > News
Catalyst Pharmaceuticals’ neuromuscular drug succeeds in seven-patient trial
By PBR Staff Writer
Catalyst Pharmaceuticals said its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a debilitating neuromuscular disease, met the main goals of a study.
Contract Research & Services > Clinical Trials > News
AstraZeneca's Lynparza shows significant survival benefit in ovarian cancer study
By PBR Staff Writer
A phase 3 clinical trial evaluating AstraZeneca's PARP inhibitor Lynparza (olaparib) as maintenance therapy in ovarian cancer demonstrated a pronounced extension in survival compared to placebo.
Contract Research & Services > Clinical Trials > News
Indivior plans to file NDA for schizophrenia drug in Q4 2017
Indivior has unveield positive top-line 12-Month phase 3 results confirming long-term safety profile of RBP-7000 in patients with schizophrenia.
Contract Research & Services > Clinical Trials > News
16-30 of 4049 results